Changzhou Qianhong Biopharma CO.,LTD Reports Earnings Results for the Full Year Ended December 31, 2021
April 22, 2022 at 03:13 pm IST
Share
Changzhou Qianhong Biopharma CO.,LTD reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 1,873.91 million compared to CNY 1,667.07 million a year ago. Revenue was CNY 1,874.94 million compared to CNY 1,667.61 million a year ago. Net income was CNY 181.08 million compared to net loss of CNY 132.02 million a year ago. Basic earnings per share from continuing operations was CNY 0.15 compared to basic loss per share from continuing operations of CNY 0.11 a year ago. Diluted earnings per share from continuing operations was CNY 0.15 compared to diluted loss per share from continuing operations of CNY 0.11 a year ago.
Changzhou Qianhong Biopharma CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of freeze-drying powder, freeze-drying powder injections, small volume injections, tablets, hard capsules, granules and bulk drugs, among others. The Company mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The Company distributes its products within domestic market and to overseas markets.